Home > About > Our Board Sub Committees
Prof Phil Hansbro - Centenary Institute

Our Board Sub Committees

Centenary Commercialisation Committee

Dr C Glenn Begley
MB, BS, PhD, FRACP, FRCPA, FRCPath, FAHMS

Dr Begley currently advises several biotechnology companies, academic groups and served as Chief Scientific Officer at two small biotechnology companies, From 2002-2012, he was Vice-President and Global Head of Hematology/Oncology Research at Amgen, responsible for building, directing and integrating Amgen’s 5 research sites. During this time he became interested in the issue of research integrity and scientific reproducibility. Before joining Amgen he had over 20 years of clinical experience in medical oncology and hematology.

He is Board Certified in Australia as a Medical Oncologist and Hematologist, has a PhD in cellular and molecular biology.


Prof Mark Gorrell
Professor Mark Gorrell heads the Liver Enzymes in Metabolism and Inflammation Program. He trained in cell biology, virology, immunology and protein biochemistry at Australian National University, University of Melbourne and Johns Hopkins University. His research is focussed upon liver cancer prevention and treatment, chronic liver disease pathogenesis, diabetes, protein and enzyme biochemistry and cell biology related to the proteases DPP4, DPP9 and fibroblast activation protein (FAP).

He has authored over 130 publications attracting H index 40, i10 index 81 and > 5,000 citations. His research experience also includes small RNA viruses, transcriptomics, proteomics and cell biology. His research was important in the development of DPP4-targetted therapies for type 2 diabetes, which are now used to treat millions of patients.

Inside Centenary Institute, he chairs the postgraduate research and equipment grants committees and is Academic Advisor for postgraduate research. Outside Centenary Institute, he is active in the International Proteolysis Society, the Gastroenterological Society of Australia, NHMRC grant reviews, and editorial boards of Journals including Scientific Reports.


Mr Bruce Grey
Mr Bruce Grey is currently Chairman of Advanced Braking Technology Limited listed on the Australian Stock Exchange, and he is a Non-Executive Director of CAP XX Limited listed on the London Stock Exchange.

He is currently a Board member of the Murdoch Children’s Research Institute and is also Chairman of the Translation and Commercialisation Committee. He is also a member of the Finance Risk and Audit Committee.

He is also a Board member of the Victorian Clinical Genetics Services a subsidiary of the Murdoch Children’s Research Institute.

For 10 years until 2009, was Chairman of a German JV between Bishop and Mercedes-Benz Lenkungen GmbH.

He has more than 20 years experience in managing industry R&D and more than 30 years experience in international commercialisation of Australian innovation. Over this period he also negotiated licence agreements in Japan, China, South Korea and the US yielding in excess of $100 million in royalties and licence fees.

In 2016 he became Chairman of the Industry Advisory Network for the University of New South Wales, School of Mechanical and Manufacturing Engineering.He is a Fellow of the Academy of Technological Scientists and Engineers and a Member of the Australian Institute of Company Directors.


Professor Philip Hogg

Prof Philip Hogg graduated with a PhD in biochemistry from the University of Queensland in 1987. Following post-doctoral training in the USA and Sweden he returned to UNSW as a NHMRC RD Wright Fellow. He is now a NHMRC Senior Principle Research Fellow and was the inaugural director of the Lowy Cancer Research Centre at UNSW. He has won several national and international awards for his research, which focuses on a fundamental chemical modification of proteins he discovered. This research has led to a potential new cancer diagnostic and a therapeutic that are in clinical testing.


Mr Jamie Nettleton
Jamie Nettleton is a partner in the Intellectual Property group at Addisons Lawyers in Sydney.  Jamie has practised law in both Sydney and London and has advised extensively in respect of the recognition, protection and exploitation of intellectual property rights, particularly in respect of new technologies.  He has a particular interest in the field of medical research and taking advantage of the opportunities that intellectual property rights afford.


Dr Chris Roberts AO (Chair)
BE (Hons), PhD, Hon DSc (UNSW), MBA, Hon DSc (Macq), FAICD, FTSE, FIEAust

Dr Roberts is the former Chief Executive Officer of Cochlear Limited and currently a Member of the Cochlear Foundation Board. He is Chairman of OncoSil Medical Limited, a Member of Innovation Science Australia, Chairman of TEDI London (a new UK based engineering school) and non-executive director of Clarity Pharmaceuticals Limited and Atmo Biosciences Pty Ltd.  He was Chairman of Research Australia (2004 – 2010). Dr Roberts has worked in the medical device industry for over 40 years in a number of senior management positions.


Prof Mathew Vadas AO FAHMS

Prof Vadas followed his medical training with a PhD at the Walter and Eliza Hall Institute in Melbourne and postdoctoral work at Harvard.

He was the Inaugural Director of the Hanson Centre for Cancer Research (now Hanson Institute) in Adelaide and has been the Executive Director of Centenary Institute since 2007.


Centenary Investment Committee

Mr Paul Chadwick

Paul Chadwick is a Managing Director and founder of Nanuk Asset Management, a Sydney based firm founded in late 2009 that specialises in global investments related to environmental sustainability.

Previously, Paul was the Managing Director of GMO Australasia where, until retirement in mid 2008, he was responsible for managing the group’s overall businesses in Australasia and leading the Systematic Global Macro investment group. Prior to GMO, he held senior roles at Westpac Investment Management and James Capel Australia. His more than thirty years career in finance has followed approximately ten years in aeronautical engineering and airline management in the USA and Australia respectively.

Paul holds degrees in Science and Aeronautical Engineering from the University of Sydney and is the current Asia Pacific board representative on the Global Council of the Alternative Investment Managers Association.


Mr Alastair Davidson (Chair)
Mr Davidson has held executive positions in the banking and financial services industry for over 30 years in the UK, US and Australia and is a member of the Institute of Chartered Accountants in Scotland.

He is an Executive of Australasian Wealth Limited, a listed asset manager in Sydney.


Ms Natasha Nankivell
Natasha Nankivell is the Managing Director and Founder at Global Alternative Funds. Ms Nankivell is also Council Member and Member of Finance and Resources Committee, University of Wollongong.

Over her career in investment banking which to date has spanned 27 years, Natasha has held senior positions at banks and other financial institutions. These include Macquarie Group, Challenger Financial Services, Merrill Lynch International and Bankers Trust Australia Limited.

Ms Nankivell studied at The University of New South Wales, where she earned her Bachelor of Science in Pure and Applied Mathematics.


Mr Tim Ryan
Mr Ryan is a director and Chairman of the Investment Committee at Nanuk Asset Management and Chairman of Orion Asset Management. He founded Orion in 2002 and has over 36 years’ professional investment industry experience.

Prior to Orion, Mr Ryan was Chief Investment Officer and a managing director at Credit Suisse Asset Management for seven years and earlier held various research and investment management roles including seven years at James Capel Australia where he was Head of Research and a Member of the Australian Stock Exchange.

Mr Ryan is a qualified accountant and holds an Economics degree from the University of Sydney.


Professor Mathew Vadas AO FAHMS
Professor Vadas followed his medical training with a PhD at the Walter and Eliza Hall Institute in Melbourne and postdoctoral work at Harvard.

He was the Inaugural Director of the Hanson Centre for Cancer Research (now Hanson Institute) in Adelaide and has been the Executive Director of Centenary Institute since 2007.


Centenary Risk and Audit Committee

Mr Michael  Coleman (Chair)

Michael Coleman is an experienced director and Chairman. He is a pragmatic risk manager and Audit Committee expert specialising in financial services, property, funds management and media.

Michael Coleman is a non-executive Director and Chairman of the Audit Committee, Macquarie Group Limited and Macquarie Bank; a member of the Audit Committee, Reserve Bank of Australia; Director and Chairman of the Audit Committee, Legal Aid NSW; Adjunct Professor of Business, UNSW; National Board Member and Chairman of Audit Committee and NSW Councillor, Australian Institute of Company Directors; Chairman of Planet Ark Environmental Foundation; and Chairman of Bingo Industries Limited.

He retired from KPMG in 2011 after a 40-year career which included 30 years as a partner, executive experience as National Managing Partner for both Audit and Risk Management & Regulation in Australia and head of risk and regulatory management across Asia. As an audit partner Michael had extensive financial reporting and corporate governance experience across a range of industry sectors, but especially banking & finance, funds management, property and media in addition to significant government and regulatory engagement.


Ms Elizabeth Dibbs
Ms Dibbs held senior legal positions throughout her career, including General Counsel of PricewaterhouseCoopers prior to her retirement.

Ms Dibbs now focuses her energy on the government and not-for-profit sectors.

She is Deputy Chancellor of Western Sydney University and Chair of its Audit & Risk Committee, Chairman of United Way Australia and a member of Chief Executive Women.


Mr Peter Sutherland
Peter Sutherland has over 30 years experience in financial services, both in Australia and overseas, principally the United Kingdom and United States.

Peter has held senior risk management, compliance and audit roles in the Commonwealth Bank of Australia (CBA) and Insurance Australia Group, and was Chief Risk Officer of Colonial First State from 2009 to 2014. Most recently he has led conduct programs within CBA’s Wealth Management business unit and coordinated the work of independent experts engaged by the CommInsure business. During his eight years at CBA Peter was a member of and chaired a number of subsidiary CBA boards and board committees. He has extensive experience in working in highly regulated environments.

Prior to joining the commercial sector Peter worked with PriceWaterhouseCoopers for 13 years, in audit, due diligence and consulting roles.

Peter is a Chartered Accountant and Graduate of the Australian Institute of Company Directors and has post-graduate qualifications in risk management. He was an adviser to the Audit Committee of Reconciliation Australia.